Back to top
more

Replimune Group (REPL)

(Delayed Data from NSDQ)

$5.22 USD

5.22
514,122

-0.44 (-7.77%)

Updated May 24, 2024 04:00 PM ET

After-Market: $5.23 +0.01 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for REPL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Replimune Group, Inc. [REPL]

Reports for Purchase

Showing records 121 - 140 ( 191 total )

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 121

10/06/2020

Industry Report

Pages: 4

BIL October Update

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 122

09/14/2020

Industry Report

Pages: 15

Healthcare -Strategies and Therapeutic Opportunities to Address Checkpoint (IO) Resistance

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 50.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 123

09/10/2020

Industry Report

Pages: 4

BEST IDEAS LIST

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 124

08/10/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 125

08/10/2020

Company Report

Pages: 4

FY1Q21 Financials Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 126

08/10/2020

Company Report

Pages: 7

Fiscal Q1; Multiple RP1 Cohorts on Track; First Look at RP2 Around the Corner

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 127

08/07/2020

Company Report

Pages: 6

1Q20 - Steady Progress to Infect More Tumors

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 128

07/01/2020

Company Report

Pages: 4

Stock Price Appreciation Presents Profit-Taking Point; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 129

06/04/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 130

06/04/2020

Company Report

Pages: 5

RP1 + Opdivo Update Encouraging; FY2020 Financials; Raising PT to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 131

06/03/2020

Company Report

Pages: 7

Activity in IO-Refractory Skin Cancers

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 132

06/03/2020

Company Report

Pages: 7

Interim Data Highly Supportive of Registration-Directed Studies; Fiscal Q4

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 133

06/01/2020

Industry Report

Pages: 12

The Week Ahead in Life Scien

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 134

05/18/2020

Daily Note

Pages: 12

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 135

05/06/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 136

05/06/2020

Company Report

Pages: 6

What to Expect from Replimune in June?

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 137

04/27/2020

Industry Report

Pages: 3

Register for Our Webinar: ACSO Abstract Titles Review '-' April 30th at 10am ET

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 138

04/06/2020

Daily Note

Pages: 32

BEST IDEAS LIST

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 139

03/25/2020

Daily Note

Pages: 6

BEST IDEAS LIST - Adding REPL - ARVN

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 140

03/24/2020

Industry Report

Pages: 6

"Consider Reading" Vol. 8: Can An Oncolytic Virus Turn a Cold Tumor Hot?

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party